Lancet Oncology

Article	Citations
Use of artificial intelligence to enhance detection of nodal metastases	834
SABR for operable stage I non-small-cell lung cancer: comparison to surgery	585
Patients with cancer in Louisiana denied fertility preservation cover	524
Combination immunotherapy in chemotherapy in gastric cancer	498
US FDA proposes stronger laboratory test oversight	460
Correction to Lancet Oncol 2022; 23: 1124–26	442
COVID-19 pandemic causes cervical cancer screening crisis	412
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	387
Medical treatment for active breast cancer brain metastases	387
IVLBCL mimicking VEXAS syndrome	381
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	367
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy	345
The GLOW trial in chronic lymphocytic leukaemia	330
Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer	319
Dual therapy in metastatic castration-resistant prostate cancer	315
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply	310
Olanzapine for chemotherapy-induced nausea and vomiting control	301
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer	301
Study bolsters concerns about US FDA accelerated drug approvals	301
CAR T cells for the long run in aggressive B-cell lymphoma	299
Correction to Lancet Oncol 2021; 22: 1081–92	296
Antibody–drug conjugates in acute myeloid leukaemia: more research needed	282
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC	279
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial	271
The future of precise cancer chronotherapeutics	271

The silent malignant mesothelioma epidemic: a call to action	259
Navigating the complexity: reflections on the development of perioperative cancer treatments	254
Health insurance system in Japan faces risk of politicisation	241
A new generation of comprehensive precision oncology trials	240
Survivorship after neoadjuvant chemotherapy	239
Italy to pass law on the right to be forgotten for cancer survivors	233
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply	233
SANO trial: innovations, risks, and unanswered questions	230
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t	227
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation	221
Concern for cancer drugs in USA–EU tariff war	219
Palliative radiotherapy for hepatic cancer pain	215
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis	206
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial	205
US Surgeon General calls for cancer warning labels on alcohol	205
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges	203
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries	201
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled,	190
Precision medicine for children with cancer	189
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi	189
Innovation in gynaecological cancer: highlighting global disparities	187
Determining the optimal use of approved drugs in oncology	184
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply	180
New national cancer registry for France	180
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study	180
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX	180
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus	180
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	177
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study	176
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult	174
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm	174
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial	173
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia	172
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial	169
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial	168
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma under	164
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised,	163
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase	163
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery	161
Focus where it matters: turning insights into advocacy	159
Decentralised, point-of-care CAR-T for multiple myeloma	157
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study	155
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer	154
A biobank perspective on use of tissue samples donated by trial participants	154
Common Sense Oncology: including everyone	152
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?	149
Gestational trophoblastic neoplasia: one size does not fit all – Authors' reply	146
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply	145
Essential anticancer medicines for children: defining what matters most for Europe	144
Importance of clinical research for the UK's 10-year cancer plan	143

Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:	142
Radiotherapy with genomic-adjusted radiation dose	141
Mantle cell lymphoma: is it time for risk-adapted treatment?	140
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire	139
Radiotherapy with genomic-adjusted radiation dose	139
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer	135
Lung cancer rates highest among British Bangladeshi men	134
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	134
Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis	134
Antimicrobial resistance in patients with haematological malignancies: a scoping review	132
WHO reports health service disruptions due to suspensions of aid	131
Balancing clinical benefit and social value: challenges in HTA assessments	130
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer	130
Cancer on the agenda during IAEA Director General's visit to Chile	128
Daratumumab maintenance in patients with myeloma	127
Challenges and prospects for cancer treatment in prison settings	126
Correction to Lancet Oncol 2023; 24: e242	124
2022 ASTRO annual meeting	122
Correction to Lancet Oncol 2020; 21: 699–709	122
Clearing the radiotherapy backlog: innovation to pave the way	121
A growing vulvar mass in a post-menopausal woman	118
Lebanon faces critical shortage of drugs	118
Shortages of essential medications for children with cancer in Colombia	117
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA	116
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations	115
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer	113
Alcohol and the global burden of cancer: what are we missing?	113
India rolls out HPV vaccination	111
Syrian cancer patients regain treatment access in Türkiye	111
The challenges of cancer care for the LGBTQ+ community	111
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial	110
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update	108
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study	108
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti	107
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group	106
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo	106
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study	103
Radiotherapy and conflict: from disruption to expansion and hope	102
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit	102
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial	101
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis	101
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	100
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra	99
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study	98
Oral contraceptives and risk of liver cancer	98
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK	96
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial	96
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup	94
Managing immune checkpoint inhibition in transplant recipients	90
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer	90
Endometrial cancer: the individual approach	90
6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting	89
AACR Annual Meeting 2023	88
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply	88
The thin border between individual and collective ethics: the downside of GDPR	88
Correction to Lancet Oncol 2021; 22: 1497–98	87
ROAR trial: which treatment is effective after progression?	87
Correction to Lancet Oncol 2024; 25: e126–35	86
Shortage of cancer drugs in Mexico	85
Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis	81
Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma	80
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply	80
Promoting cancer prevention through World Cancer Day in Nigeria	79
On a precipice: the UK's broken health-care system	79
Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply	79
Study of the Veterans Affairs Health Care System highlights the impact of COVID-19 on cancer diagnoses in the USA	79
Medical debt of people with cancer in the USA	79
Pembrolizumab monotherapy for advanced chordoma – Authors' reply	77
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care	77
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?	76
Screening for breast cancer brain metastases	75
Internationally trained doctors in the USA	74
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?	72
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting	72
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group	72
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommen	71
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-co	71
Mozambique takes on cancer burden challenges	71
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial	71
South Africa's new tobacco and e-cigarette control bill	71

Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment	70
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose	70
Correction to Lancet Oncol 2023; 24: 1181–95	70
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study	69
Transforming cancer: behind the scenes at the Crick Institute	68
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, singl	68
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402)	68
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-lab	67
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry	67
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label,	67
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply	66
Code of practice needed for samples donated by trial participants – Sponsor's reply	66
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop	66
Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases	66
Quality control and childhood cancer medicines	65
Correction to Lancet Oncol 2016; 17: 484–95	65
Pilot cancer programmes in Côte d'Ivoire, Kenya, and Zimbabwe	65
Correction to Lancet Oncol 2023; 24: e472–518	65
Correction to Lancet Oncol 2022; 23: 1297–307	65
Correction to Lancet Oncol 2023; 24: 91–106	65
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply	64
US lawmakers call on Biden Administration to lower the price of enzalutamide	64
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply	64
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply	64
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study	63
Sintilimab plus IBI305 for hepatocellular carcinoma	63
Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study	63
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma	63
Stereotactic ablative radiotherapy for primary kidney cancer	62
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia	62
PSMA-PET research: addressing challenges and prospects – Authors' reply	61
18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply	61
New evidence for brain cancer risk after a single paediatric CT scan	61
US legislation might soon allow easier access to cancer medications	61
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply	61
Problems with catch-up HPV vaccination after resumption of proactive recommendations	60
Essential medicines list in national cancer control plans: a secondary analysis from a global study	60
American Lung Association calls for expanded insurance coverage for lung cancer screening	59
Challenging cancer through poetry	59
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges	58
Anticipating the future of cancer care in Trump's America	58
Qatar national cancer care and research: pioneering strategies for global health excellence	57
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	56
Rwanda provides free treatment to all cancer patients	56
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma – Authors' reply	55
Abemaciclib for malignant pleural mesothelioma – Authors' reply	54
Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer	54
Sharing a personal story behind brain cancer	54
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic	54
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE	52
Management of locally advanced gastric cancer	52
Immunotherapy: balancing the risks and benefits	52
Sharp increase in patients waiting months for urgent cancer treatment	52
Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer	51
Poor cancer care in Zimbabwe	51
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-02	51
HPV vaccine roll-out in Nigeria and Bangladesh	50
ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma	50
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?	50
US Clean Air in the firing line	50
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean	50
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease	50
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, op	50
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?	49
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-a	49
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label,	49
The changing global landscape of national cancer control plans	49
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial	48
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial	48
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label	47
Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment	47
US cancer research might never recover from proposed Trump funding cuts	47
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study	46
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial	46
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim resul	46
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial	46
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study	46
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised	46
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-	45
Secondary prevention of anthracycline cardiotoxicity in childhood cancer survivors	45
Thank you to The Lancet Oncology's reviewers in 2022	45
Thoracic CT follow-up after non-small-cell lung cancer resection	44
Improved cancer coverage for firefighters in Western Australia	44
Cancer in sub-Saharan Africa: key research and action gaps	44
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer	43
Place of death of people with cancer in 12 Latin American countries: a total population study using national death registers	43
Transforming Canada's role in global cancer control	43
Losing my brother, finding myself	43
Indonesia and the Philippines take steps to control cancer	43
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	43
Correction to Lancet Oncol 2022; 23: 393–405	42
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer – Authors' reply	42
Treatment of Richter transformation—immunotherapy to the rescue?	42
Horizon 2020 evaluation highlights benefit of cross-border research but points to areas for improvement	42
Correction to Lancet Oncol 2024; 25: 317–25	41